Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDUCE denosumab reduced dose-density maintenance study in unresectable giant cell tumor of bone
NL-OMON47949Phase 2Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of denosumab, sponsored by European Organisation for Research and Treatment of Cancer. Started Feb 2020; status: active, not recruiting.
02
Drugs
denosumab
Beyond the preview
Go deeper on NL-OMON47949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47949.